Uniqure NV (QURE NASDAQ) stock market data APIs
$57.7315
2.05(3.6%)
as of October 17, 2025
Try our APIs with
free plan!
Uniqure NV Financial Data Overview
Price chart is built with
Anychart
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prev. Close
57.7315
Open
59.7851
High
60.7133
Low
58.1383
52 wk Range
5.35-65.14
Market Cap
3 696 M
Shares Outstanding
61 604 K
Revenue
14 337 K
EPS
-0.69
Beta
0.563
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Uniqure NV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Uniqure NV data using free add-ons & libraries
Get Uniqure NV Fundamental Data
Uniqure NV Fundamental data includes:
- Net Revenue: 14 337 K
- EBITDA: -146 439 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-07-29
- EPS/Forecast: -0.89
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Uniqure NV News
New
Jim Cramer on uniQure: “This One Has Too Many Questions for Me Up Here”
uniQure N.V. (NASDAQ:QURE) is one of the stocks Jim Cramer recently talked about. A caller asked whether to buy, hold, or take profits in the stock after the release of clinical data, which indicated ...
Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders
Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological dis...
uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission
We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. uniQure N.V. is one of them. uniQure N.V. (NASDAQ:QURE) is a leading gene therapy company focused on developi...
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical nee...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
